Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIQSNX321)
  Drug Name Cabergoline Drug Info Trimethaphan Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antineoplastics Antihypertensive Agents
  Structure

 Mechanism of Cabergoline-Trimethaphan Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Cabergoline Trimethaphan
      Mechanism 1 Antihypertensive agent Antihypertensive agent
Neuronal acetylcholine receptor  Antagonist
      Key Mechanism Factor 1
Factor Name Neuronal acetylcholine receptor Structure Sequence
Protein Family Ligand-gated ion channel (TC 1.A.9) family
Protein Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Cabergoline and Trimethaphan 
      Mechanism 2 Hypotensive effects Antihypertensive agent
Neuronal acetylcholine receptor  Antagonist
      Key Mechanism Factor 2
Factor Name Neuronal acetylcholine receptor Structure Sequence
Protein Family Ligand-gated ion channel (TC 1.A.9) family
Protein Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Cabergoline and Trimethaphan 

Recommended Action
      Management Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1 Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6. [PMID: 2211552]
2 Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139. [PMID: 2005082]
3 Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1. [PMID: 1770159]